Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 5/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14232278 | 1.00 | CYP2C9 (0.33) | CYP2C9CYP2D6PLAUCYP1A2CYP19A1 | |
| SCHEMBL14119902 | 1.00 | CYP2C9 (0.33) | CYP2C9CYP2D6PLAUCYP1A2CYP19A1 | |
| SCHEMBL14917059 | 0.80 | PLAU (0.54) | CYP2C9CYP2D6PLAUCYP1A2CYP19A1 | |
| SCHEMBL30236666 | 0.70 | CYP2C9 (0.40) | CYP2C9CYP2D6PLAUCYP1A2CYP19A1 | |
| SCHEMBL24387226 | 0.70 | PLAU (0.54) | CYP2C9CYP2D6PLAUCYP1A2CYP19A1 | |
| SCHEMBL29749760 | 0.70 | PLAU (0.54) | CYP2C9CYP2D6PLAUCYP1A2CYP19A1 | |
| SCHEMBL14119964 | 0.70 | PLAU (0.39) | CYP2C9CYP2D6PLAUCYP1A2CYP19A1 | |
| SCHEMBL29414008 | 0.68 | CYP2C9 (0.35) | CYP2C9CYP2D6PLAU | |
| SCHEMBL28852779 | 0.68 | CYP2C9 (0.35) | CYP2C9CYP2D6PLAU | |
| SCHEMBL28356992 | 0.67 | BTK (0.35) | CYP2C9CYP2D6CYP1A2CYP19A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309746-A1 | TRIAZOLOPYRIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-12-06 | — | — | US | disclosed |
| WO-2012163724-A1 | TRIAZOLOPYRIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309746-A1 | TRIAZOLOPYRIDINE COMPOUNDS | SYK, BTK, IRAK4 | CYP2C9 2996/4885CYP2D6 1865/4885PLAU 4620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.